Naturhouse Health SA

Naturhouse Health SA maintains a strong liquidity position, with a current ratio of 1.65, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score further supports this, showing a low liquidity risk. However, the company's free cash flow is negative at -6.522 million EUR, which may indicate that capital expenditures and other operational costs are outpacing cash inflows. In terms of profitability, Naturhouse Health SA demonstrates a return on equity of 56.86% and a return on assets of 30.19%, both of which are strong indicators of efficient use of equity and assets to generate profit. The company's operating income of 13.418 million EUR and net income of 10.094 million EUR suggest a healthy margin, although the exact comparison to industry medians is not provided in the available data. The company's revenue is not segmented by product or geographic region in the provided data, so the extent of revenue concentration in specific segments or regions cannot be determined. However, the company's operations are likely concentrated in the European market, given the EUR financial reporting and the company's listing on the Madrid Stock Exchange. Looking at the growth trajectory, the company's revenue for the latest period is reported at 47.629 million EUR, and the analyst estimate for the last actual revenue is 49.425 million EUR, suggesting a slight positive growth trend. The outlook for the current and next fiscal years is not explicitly provided, but the company's strong profitability and liquidity position may support continued growth. The risk assessment indicates a low risk of dilution and no immediate filing-based liquidity or dilution flags were detected. The company's debt to equity ratio of 0.14 suggests a conservative capital structure with minimal long-term debt, which reduces financial risk. Recent events, such as filings or transcripts, are not detailed in the provided data, so no specific recent developments can be cited. However, the company's financial health and low risk profile suggest that it is well-positioned to navigate potential market challenges.